Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 439, 274-275 (19 January 2006) | doi:10.1038/439274a; Published online 18 January 2006
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Academic Surgical Pathologists
- Northwestern University
- Chicago, Illinois, USA
Faculty Position in Mathematical Biology
- The Ohio State University
- Ohio, USA
Cancer biology: Signatures guide drug choice
Julian Downward1
Abstract
Cancer drugs are increasingly designed to target specific cell-signalling pathways. When, and in what combination, these drugs should be used might be judged by analysing the gene expression signature of the tumour.
Current approaches to the design of drugs against cancer assume that almost all tumours escape normal growth regulation by usurping a few of the dozen or so key cell-signalling pathways. However, pathways can be activated at different points, so it is not always easy to tell which signalling mechanism has been activated by looking for mutations in known cancer-associated genes (oncogenes, or tumour-suppressor genes).
- Julian Downward is at the Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK.
Email: downward@cancer.org.uk
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Surface versus Intracellular Polarization of Cortical CellsNature Letters to Editor (21 Oct 1967)
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3BOncogene Original Article
See all 3 matches for Research